Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
about
Acute lymphoblastic leukaemiaPotential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemiaMonoclonal antibodies in acute lymphoblastic leukemiaNelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromesCD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis.Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia.Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).Outcome of Adolescents with Acute Lymphoblastic Leukemia Treated by Pediatrics versus Adults ProtocolsReceipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens.A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.Small molecule growth inhibitors of human oncogenic gammaherpesvirus infected B-cellsAllogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia.Mutational spectrum of adult T-ALLImproving access to novel agents for childhood leukemia.Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome.Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemiaAnti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemiaXmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells.Immunotherapy for pediatric leukemia.Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumabResults of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphomaAllogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Results from a Single Center, 1993-2011.Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.Treatment of acute lymphoblastic leukemia in adolescents and young adults.Optimal pharmacotherapeutic management of acute lymphoblastic leukaemia in the elderly.Antibody therapy for acute lymphoblastic leukemia.
P2860
Q24602387-6FE7E099-5850-4C69-92E3-2126DA252E57Q26764903-87109E75-56D5-4469-914E-811097572081Q27022540-1DC55004-D25E-4A11-8AEE-7DBB94733E9AQ30240892-CDFC086E-C705-4837-BA55-FABCE7AA7068Q33730841-5DC906CA-CD86-4531-8699-652CECC806A5Q33915990-F576DBCB-9E4F-441F-9E5F-90ED24728FF1Q34300698-53EC804C-047B-46D3-8B8B-A2FE9174EB2CQ34300704-5EEBE94B-2D5E-43A2-BB8A-5BA7DED5891FQ34300854-E6ED78E8-EAE6-463E-A7FC-DD13E6A3130AQ34416178-87431D54-B7D6-4571-9C89-D6A3731FA193Q34455093-F444ADAA-97E5-484C-8405-629D4B2FBF54Q34550540-ADE9CE9A-4792-4BF8-A7FE-1D9BD76416ECQ34610024-466CC209-7F4F-4A69-B7ED-3517FDA86EFDQ34703903-39EDF904-9406-4A45-9ECF-2F4D2898E19AQ35004970-F636592B-03F8-42DA-8B42-C4696A4CEFEDQ35007967-E20192D5-EB47-4863-9BEB-D803D85C8B77Q35029453-F181306F-E07D-4958-987B-9F41C8444E81Q35550090-DCB5A5F6-C19D-4D61-8F8C-25C4D9987B75Q35688742-4CC818A3-52CF-418B-B5BC-371F25E6FB44Q35740894-C2367EA2-2B59-48DD-B475-ABEF833832F3Q35987462-C59ADB75-7695-4B1D-B9D7-60329AC9CD6DQ36006426-20CBEA8C-2F5A-4DC0-897C-6E28AAAC0464Q36131489-54251704-AEB9-48A7-9BF2-A730A0AA3B88Q36339717-20EE19A1-02EC-44AA-B972-1B2B1046F7A1Q36619703-6A4D837E-9DEC-4A56-AB8E-AEDB746F9C31Q36751420-E324F04C-3A16-4B5F-A592-018C91F97D03Q36811503-97F4C4CA-9DBC-4A30-BCF5-CB3964986629Q36834079-AEE99ACF-EDCE-47CE-B079-B976365209FEQ36913118-072B399F-67B8-4720-88AF-BE1D43EC4CBCQ36968163-9C29BB20-6BF9-43B3-80C2-A9972623115EQ37022365-B38BEA64-5249-4208-99E3-9A2C37C8FA62Q37039074-C3C8B345-73B0-444A-BF2A-098ADB100648Q37080458-8B1E5AEE-763F-4357-9336-7D4A9AD977ECQ37517482-5585F3D6-2CBE-4A5D-9FE1-8DB965598270Q37613310-002FBDB4-28D1-4119-9766-3C181FCDECE6Q37682126-F0FC6A80-E68D-40D4-A09D-B1E3FBB23F00Q37883008-314583BA-AFBB-498F-98C4-C76AAF0AC738Q37899785-20810C83-8041-429C-9985-F23BF7142A8FQ37931235-4F17B4E7-ADC8-475B-9C1F-2822AAD1C897Q37994136-C8441255-C63B-4F27-BEDD-B82B3A31EC7B
P2860
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Chemoimmunotherapy with a modi ...... acute lymphoblastic leukemia.
@ast
Chemoimmunotherapy with a modi ...... acute lymphoblastic leukemia.
@en
Chemoimmunotherapy with a modi ...... acute lymphoblastic leukemia.
@nl
type
label
Chemoimmunotherapy with a modi ...... acute lymphoblastic leukemia.
@ast
Chemoimmunotherapy with a modi ...... acute lymphoblastic leukemia.
@en
Chemoimmunotherapy with a modi ...... acute lymphoblastic leukemia.
@nl
prefLabel
Chemoimmunotherapy with a modi ...... acute lymphoblastic leukemia.
@ast
Chemoimmunotherapy with a modi ...... acute lymphoblastic leukemia.
@en
Chemoimmunotherapy with a modi ...... acute lymphoblastic leukemia.
@nl
P2093
P2860
P50
P356
P1476
Chemoimmunotherapy with a modi ...... acute lymphoblastic leukemia.
@en
P2093
Carlos Bueso-Ramos
Deborah A Thomas
Jeffrey L Jorgensen
Rebecca Garris
P2860
P304
P356
10.1200/JCO.2009.26.9456
P407
P50
P577
2010-07-26T00:00:00Z